Condition
Glioma of Brainstem
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Unknown1
Recruiting1
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT04196413Phase 1Recruiting
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
NCT01884740Phase 1Terminated
Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
NCT03392545Phase 1Unknown
Combination of Immunization and Radiotherapy for Malignant Gliomas (InSituVac1)
Showing all 3 trials